Fig. 4: Isoform specific drug sensitivities in cell line models. | Leukemia

Fig. 4: Isoform specific drug sensitivities in cell line models.

From: Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

Fig. 4

a Scatter plot comparing average drug sensitivity score (DSS) of p190-Ba/f3 and p210-Ba/f3 cells. Drug sensitivity and resistance testing (DSRT) experiments have been performed in triplicates for each setting. Color indicates different drug families (primary targets). b Dose response curves showing drug responses of p190-Ba/f3 (red) and p210-Ba/f3 (blue) cell lines to LCL161 (IAP inhibitor), FRAX486 (PAK inhibitor), dasatinib (TKI with Src inhibitory activity) and dexamethasone (glucocorticoids). Concentrations of drugs are indicated in nM. Drug responses to other drugs from the indicated families are available in Supplementary Fig. 4. c Scatter plot comparing average drug sensitivity score (DSS) of p190-HPC-LSK and p210-HPC-LSK cells. Drug sensitivity and resistance testing (DSRT) experiments have been performed in triplicates for each setting. Color indicates different drug families (primary targets). d Dose response curves showing drug responses of p190-HPC-LSK (red) and p210-HPC-LSK (blue) cell lines to LCL161 (IAP inhibitor), FRAX486 (PAK inhibitor) and dasatinib (TKI with Src inhibitory activity). Concentrations of drugs are indicated in nM.

Back to article page